Építés alatt – nem éles oldal
Belépés
Visszavonva2. fázis

Effect of iNO in Patients With Submassive and Massive PE

A legfontosabb adatok

Ki végzi
University of California, Los Angeles
Hol
Los Angeles (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
2. fázis
Kezdés
2026. jún. 1.
Várható befejezés
2028. jún. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • inhaled nitric oxide (iNO)
A regiszteradat frissítve
2026. március 18.
Miért állt le
no sponsor support

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • Patient ≥ 18 years of age
  • The patient or patient's surrogate decision maker must understand and sign the informed consent form (ICF)
  • Hospitalized (Emergency Room (ER) or inpatient) with:
  • Imaging (computed tomography pulmonary angiography (CTPA) or ventilation/perfusion (VQ) lung scan) proven acute pulmonary embolism (PE)
  • PE meets the following intermediate risk PE criteria (or massive, see below):
  • Troponin > .1 AND
  • Imaging (computed tomography (CT) or transthoracic echocardiogram (TTE)) signs of RV compromise (at least 1 of the following):
  • RV:LV>1 on TTE or CTPA OR RV dilation (TTE or CTPA OR RV dysfunction on TTE
  • Massive PE
  • Intensive care unit (ICU) level of care (Patient moving to ICU, ICU level of care in ER, or currently in ICU)
  • Ability to comply with study protocol in investigator's judgement

Ki nem vehet részt

  • Patients already on iNO prior to study enrollment
  • Known allergy to iNO
  • Any serious medical condition of lab abnormality that, in the investigator's judgement, precludes the patient's safe participation in the study
  • Pregnancy or breastfeeding
  • Inability to administer iNO through current mode of O2 delivery (i.e. BiPAP)
  • Active hemoptysis
  • Methemoglobin reductase deficiency
  • Unable to obtain consent or patient or patient surrogate decision maker declines

Helyszínek itt: Egyesült Államok

  • Ronald Reagan UCLA Medical CenterLos Angeles, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

A single center study to evaluate the effect of inhaled nitric oxide (iNO) on pulmonary dynamics in patients presenting with imaging confirmed intermediate/submassive or massive pulmonary embolism (PE). The target enrollment is 20 subjects at Ronald Reagan UCLA Medical Center. PE patients undergoing catheter-based intervention will be administered iNO during their intervention and pulmonary hemodynamic measurement will be measured before, during, and after iNO administration (Invasive Cohort). Patients who are not undergoing catheter-based intervention will also be administered iNO and will have pulmonary hemodynamics, blood pressure, and heart rate measured non-invasively (Non-Invasive Cohort).

A vizsgálat 2 csoportja

  • Interventional Radiology Arm (Invasive Cohort)Már használt kezelés, összehasonlításként

    Interventional radiology (IR) will perform a right heart catheterization (RHC) as part of a planned IR procedure. Bedside apical 4 chamber view (RV:LV ratio) will be recorded using an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform. The Butterfly iQ+ (one possible ultrasound device which may be used) is a single-probe, whole-body ultrasound device. After initial measurements, inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The same measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes.

    Kezelés: inhaled nitric oxide (iNO)

  • Non-intervention Arm (Non-invasive Cohort)Már használt kezelés, összehasonlításként

    Vitals including O2 amount and modality, blood pressure, pressor name, dose, and rate will be recorded. If the patient is intubated, the name, dose, and rate of sedation and analgesia will be recorded. If the patient is not intubated, name and dose amount of sedation will be recorded. Arterial blood gas will be obtained if an A-line is placed. Bedside apical 4 chamber view will be recorded (RV:LV ratio) with an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform. This data will be obtained before, during iNO administration, and after iNO has been withheld for 2 minutes.

    Kezelés: inhaled nitric oxide (iNO)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Study to Evaluate the Role of Inhaled Nitric Oxide (iNO) on Pulmonary Hemodynamics in Patients With Intermediate/Submassive and Massive Pulmonary Embolism (PE)
A regiszteradat frissítve
2026. március 18.